A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

NCT04243785 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions

DRUG: BTX-A51
DRUG: Azacitidine

Sponsor

Edgewood Oncology Inc.